China Renews Reimbursement for Three Hutchmed Drugs

MT Newswires Live

2025/12/08

Hutchmed (HKG:0013) said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.

Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.

Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.

The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2589073678"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589073678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589073678?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 09:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589073678","market":"sg","top_or_hot":-1,"title":"China Renews Reimbursement for Three Hutchmed Drugs","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (HKG:0013) said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.</p><p>Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.</p><p>Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.</p><p>The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Renews Reimbursement for Three Hutchmed Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Renews Reimbursement for Three Hutchmed Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 09:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hutchmed (HKG:0013) said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.</p><p>Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.</p><p>Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.</p><p>The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589073678","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589073678","pubTimestamp":1765157215,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed  said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1587":"次新股","BK1191":"制药","00013":"和黄医药","BK1588":"回港中概股"},"translate_title":"中国续签和黄医药三种药物的报销","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":0.9},"content_text":"Hutchmed (HKG:0013) said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}